Navigation Links
Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
Date:6/30/2008

NAPA, Calif., June 30 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced it has reached an agreement to terminate its marketing agreement with Triax Aesthetics LLC ("Triax") for Pyratine-6(TM) on most favorable terms. These terms include the return of $1,125,000 in cash from Triax and a service provider, return of all intellectual property, product inventory and promotional materials, access and ownership of all accounts opened, remittance of all proceeds of product sales through the agreement termination date, rights to use the Triax Aesthetics name for one year in conjunction with sales of existing packaged product inventory and a non-competition agreement from Triax and certain related parties prohibiting them from selling any topical non monograph products used for antiaging purpose and/or in connection with acne rosacea for a period of two years.

A spokesperson for Triax Aesthetics commented, "We sincerely believe that Pyratine-6(TM) is a product with significant advances over the competition in the marketplace. We agreed with Senetek that there are better candidates for the distribution of this product. We will do everything possible to help make Pyratine-6(TM) a continued success."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek PLC Announces Key Personnel Appointments
2. Senetek PLC Reports 2007 Financial Results
3. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
4. Senetek PLC Announces Launch of New Website
5. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
6. Senetek PLC Reports Third Quarter 2007 Financial Results
7. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
8. Boiron Laboratories Disputes British Journals Editorial on Homeopathy
9. Datasci and etrials Worldwide Announce Settlement in Patent Dispute; Licensing Agreement Now in Place
10. American Association for Homecare Disputes Validity of Internet Power Wheelchair Prices as Basis for Reimbursement of Services in Medicare
11. Maverick Marketers Defy Economic Slowdown
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign ... for the Access to Contraception for Women Servicemembers and Dependents Act of 2017. ... (D-CA), will help to ensure that all members of the Armed Forces receive ...
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... UT (PRWEB) , ... April 28, 2017 , ... Beginning ... some of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ... be changing the formula in the following ways:, , Removal ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it ... 19 hours without sleep can compromise motor reaction time, which can increase the risk of ... is sharing the following tips from the NSF to help you sleep better and feel ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology: